Originally published July 8 2005
WellGen, Inc. and Rutgers University expand research capabilities in nutrigenomics
by Mike Adams, the Health Ranger, NaturalNews Editor
WellGen, Inc., a biotechnology company using nutrigenomics to develop proprietary wellness products, has expanded both its research contract and licensing agreement with Rutgers to include several new bioactive compounds and novel technologies, such as anti-inflammatory compounds and an innovative technology for in-vitro validation of anti-inflammatory compounds.
WellGen, Inc., a biotechnology company using nutrigenomics to develop proprietary wellness products, announced today that it has renewed and expanded both its research contract and licensing agreement with Rutgers, The State University of New Jersey.
The license agreement was expanded to include several new bioactive compounds and novel technologies including numerous pending patent applications in the area of nutrigenomics, such as anti-inflammatory compounds and an innovative technology for in vitro validation of anti-inflammatory compounds.
WellGen's products include an anti-arthritis compound and an anti-colon cancer compound, which will complete human clinical trials this year.
WellGen has also developed preclinical compounds in the areas of anti-obesity, exercise recovery and exercise performance.
"We worked hard to develop a relationship with Rutgers that inspires true innovation.
Some chemicals found in commonly consumed foods are dietary signals that influence gene and protein expression and, subsequently, metabolite production.
It is possible to identify foods and food ingredients that alter expression of genes associated with onset or proliferation of various diseases and conditions.
WellGen's core intellectual property, licensed from Rutgers, was developed by the nationally recognized Rutgers Food Science department in conjunction with the Rutgers Chemistry department, School of Pharmacy, and the University of Medicine and Dentistry of New Jersey.
Along with the screening technology, WellGen gained exclusive access to bioactive compounds found to positively regulate expression of specific genes associated with disease.
WellGen intends to continue funding research at Rutgers University for the ongoing discovery and pre-clinical validation of new bioactive compounds and technologies and to complete extensive safety and efficacy tests on their products, culminating in human clinical trials.
"We are excited about the progress at WellGen.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml